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doi:10.1Objective: Pulsatile left ventricular assist devices have been shown to effectively reduce pulmonary hypertension
in patients with end-stage heart failure. However, it remains to be seen whether newer continuous-flow left
ventricular assist devices have a similar effect on pulmonary hypertension. The objective of this study was to
determine whether the HeartMate II (Thoratec Corp, Pleasanton, Calif), a continuous-flow left ventricular assist
device, is effective in improving pulmonary hemodynamics in the period after left ventricular assist device sup-
port and posttransplant.
Methods: Fifty patients with end-stage heart failure underwent HeartMate II left ventricular assist device place-
ment as a bridge to transplant.We evaluated their pulmonary hemodynamics with right-sided heart catheterization
at baseline, after left ventricular assist device placement, and after heart transplant.
Results: The mean age of patients was 53.7  13.5 years. Ischemic etiology was present in 60% of the patients.
After left ventricular assist device placement (mean duration, 135 60 days), mean systolic and diastolic pulmo-
nary artery pressures decreased significantly from a baseline of 55.2  13.4 mm Hg and 27.3  6.8 mm Hg,
respectively, to 35.9 10.8 mm Hg and 15.8 6.5 mm Hg, respectively (P<.001). Similarly, mean pulmonary
vascular resistance decreased significantly from a baseline of 3.6  1.9 Woods units to 2.1  0.8 Woods units
(P< .001). Posttransplant pulmonary hemodynamics also remained within normal limits, even in patients
with previously severe pulmonary hypertension.
Conclusion: Continuous-flow left ventricular assist devices effectively improve pulmonary hemodynamics
associated with end-stage heart failure. Moreover, pulmonary hemodynamics remain within normal limits in
the posttransplant period, even in patients with severe pulmonary hypertension. Therefore, adequate left ventric-
ular decompression achieved with newer left ventricular assist devices can reverse significant pulmonary
hypertension in patients with end-stage heart failure, making them eligible for cardiac transplantation. (J Thorac
Cardiovasc Surg 2010;140:447-52)T
XOrthotopic heart transplantation is an established treatment
modality for patients with end-stage heart failure. An
increasing number of patients are being successfully bridged
to a heart transplant by a left ventricular assist device
(LVAD).1 Most patients who have undergone LVAD place-
ment as a bridge to transplant (BTT) in the United States
have historically been supported by pulsatile, volume-
displacement devices, such as the HeartMate XVE (Thoratec
Corp, Pleasanton, Calif).2 These devices provide excellent
hemodynamic support and improve patient survival, yet
they have significant constraints, including the need for ex-
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The Journal of Thoracic and Caa large-diameter percutaneous lead, and audible pump oper-
ation. Even more important, their long-term mechanical
durability is limited, frequently requiring reoperations for
device exchange. The newer HeartMate II LVAD, which in-
corporates continuous flow, rotary pump technology, repre-
sents the next generation of devices. The focus of new
pumps is enhanced durability and quality of life for extended
periods of circulatory support. A major advantage of these
new pumps is their small size, thereby extending therapy
to underserved patient populations, including women and
even some children.3,4
Despite several advances in the field of heart transplanta-
tion, the presence of pulmonary hypertension (PH) remains
a risk factor for adverse outcomes posttransplant, primarily
related to acute donor right-sided heart failure.5-7 In some
of these patients, severe PH is reversible by pharmacologic
means; however, there are limitations of pharmacologic
therapies, such as preexisting systemic hypotension. By
unloading the left ventricle, LVADs can reduce elevated
pulmonary artery pressures. Pulsatile LVADs as a BTT
have been proven to be beneficial in reversing PH in
patients, but published data on the efficacy of lowering PHrdiovascular Surgery c Volume 140, Number 2 447
Abbreviations and Acronyms
BTT ¼ bridge to transplant
DPAP ¼ diastolic pulmonary artery pressure
LVAD ¼ left ventricular assist device
PH ¼ pulmonary hypertension
PVR ¼ pulmonary vascular resistance
SPAP ¼ systolic pulmonary artery pressure
TPG ¼ transpulmonary gradient
Cardiothoracic Transplantation John et al
T
Xusing continuous-flow devices are limited. Previous studies
showed that axial flow devices provide similar degrees of
pressure unloading, but less volume unloading, of the left
ventricle compared with pulsatile devices. Such findings
may have significant implications for patients with severe
PH that is medically unresponsive. Also unknown is the
degree of PH that may exist or recur after heart transplanta-
tion and LVAD removal. We report our initial experience,
based on a prospective, single-center study, regarding the
efficacy of the HeartMate II LVAD to effectively improve
pulmonary hemodynamics in the period after LVAD support
and in the posttransplant period. Our study included 50 pa-
tients with a BTT and end-stage heart failure at the Univer-
sity of Minnesota Medical Center.MATERIALS AND METHODS
Patients
From October 1, 2005, to January 2009, a total of 70 patients (mean age,
57.24 14.2 years) underwent HeartMate II placement at the University of
MinnesotaMedical Center (BTT in 50 patients, destination therapy in 10 pa-
tients, and LVAD exchange for a failed XVE model in 10 patients). The
total duration of LVAD support was 352.1 patient-months (mean duration,
7.8  5.4 months).
This study focuses on the 50 patients with a BTT who underwent Heart-
Mate II placement. Patients with end-stage heart failure who were on our
transplant waiting list were eligible for study enrollment. The protocol for
the study was approved by the Food and Drug Administration and the insti-
tutional review board at the University of Minnesota Medical Center.
Patient consent for data collection and reporting was obtained by a standard
informed consent process.
HeartMate II
The HeartMate II consists of an internal blood pumpwith a percutaneous
lead that connects the pump to an external system driver and power source.
The pump has an implant volume of 63 mL and generates up to 10 L/min of
flow at a mean pressure of 100 mm Hg. The details of the HeartMate II
function and the implant technique have been described.5
Hemodynamic Evaluation
We evaluated patient hemodynamics with right-sided heart catheteri-
zation at baseline, 3 months after LVAD, and 1 month after transplant.
By using the Swan-Ganz catheter (Baxter Healthcare, Irvine, Calif),
we obtained measurements while the patient was at rest in a supine po-
sition. We defined severe PH by pulmonary vascular resistance (PVR) 4
or more Woods units or by transpulmonary gradient (TPG) 15 mm Hg or
greater.448 The Journal of Thoracic and Cardiovascular SurgDevice Management
Device management reflects our local practice at the University of
Minnesota. We performed all measurements with the device on fixed-rate
speed. The rpm rate of the HeartMate II was set to provide adequate cardiac
output and achieve optimal left ventricular decompression while maintain-
ing a pulsatility index greater than 3.5 to 4. In addition, we usually adjusted
the fixed-rate speed of the HeartMate II to maximize left ventricular decom-
pression and to improve cardiac output, simultaneously attempting to allow
for at least a 1:3 ratio of aortic valve opening. We optimized the speed both
hemodynamically and echocardiographically at the time of LVAD place-
ment and if clinical events (eg, new symptoms or suction events) warranted
further adjustment.
All patients were on standard heart failure therapy, including antiarrhyth-
mic therapy as per our usual practice. Anticoagulation involved a combina-
tion of warfarin and aspirin. Defibrillator or biventricular pacing settings
were not changed after LVAD placement. All patients underwent a standard
postoperative rehabilitation program.
Data Collection
With signed informed patient consent forms and study enrollment, we
collected baseline and follow-up data, including patient characteristics,
hemodynamic parameters, blood chemistry analyses, hematologic findings,
neurologic status, and concomitant medications. After patients were
discharged from the hospital, they returned to the University of Minnesota
Medical Center for follow-up, device review, and general status assessment.
Statistical Analysis
To analyze differences between hemodynamic measurements before and
after LVAD placement, we used an independent-samples test. To compare
categoric variables, we used the chi-square or Fisher’s exact test. To
compare continuous variables, we used a Student t test if normally distrib-
uted; if not, a Wilcoxon rank-sum test was used. Values are reported as
mean  standard deviation. For all data, we used the SAS System software
version 9.0 (SAS Institute, Inc, Cary, NC).RESULTS
Patient Characteristics
The mean age of the 50 patients with a BTT was 53.7 
13.6 years (range, 23–71 years). There were 34 male and
16 female patients. Among the patients with a BTT, the
cause of heart failure was ischemic in 60% (n ¼ 30) and
idiopathic in 34% (n¼ 17); 1 patient had postpartum cardio-
myopathy, and 2 patients had congenital heart disease. The
overall mean duration of HeartMate II support in the BTT
group was 281  249 days. The characteristics at baseline
for the patients with a HeartMate II BTT are summarized
in Table 1.Hemodynamic Data
Hemodynamic data at baseline (50 patients with BTT) are
shown in Table 2.Effect on Pulmonary Hemodynamics
After LVAD placement (mean duration, 135  60 days)
in the 50 patients with a BTT, the mean systolic pulmonary
artery pressure (SPAP) and diastolic pulmonary artery
pressure (DPAP) decreased significantly from a baseline of
55.2  13.4 mm Hg and 27.3  6.8 mm Hg, respectively,ery c August 2010
TABLE 1. Characteristics of patients at baseline (n ¼ 50)
Mean age, y 53.7  13.6 (range, 23–71)
Gender ratio (M:F) 34:16
Cause of heart failure
Ischemic 30 (60%)
Idiopathic 17 (34%)
Congenital 2 (4%)
Postpartum cardiomyopathy 1 (2%)
Duration of LVAD support, d 281  249 (range, 10–906)
LVAD, Left ventricular assist device.
TABLE 3. Pulmonary hemodynamics of patients with (n ¼ 18) and
without (n ¼ 32) severe pulmonary hypertension
Severe PH (N ¼ 18) Baseline Post-VAD P value
SPAP (mm Hg)* 63.3  12.5 37.0  11.1 <.001
DPAP (mm Hg)* 30.8  5.3 15.2  7.1 <.001
PVR (Woods Units)* 5.2  1.7 2.6  0.9 <.001
TPG (mm Hg)* 17.5  4.0 10.7  3.3 <.001
Normal PH (n¼32)
SPAP (mm Hg)* 49.5  10.7 35.7  10.7 <.001
DPAP (mm Hg)* 24.6  6.4 16.6  6.1 <.001
PVR (Woods Units) 2.4  0.9 1.8  0.7 .07
TPG (mm Hg) 9.0  2.5 8.7  2.7 .536
PH, Pulmonary hypertension; VAD, ventricular assist device; SPAP, systolic pulmo-
nary artery pressure;DPAP, diastolic pulmonary artery pressure; PVR, pulmonary vas-
cular resistance; TPG, transpulmonary gradient. *Statistically significant with P<.05.
John et al Cardiothoracic Transplantationto 35.9  10.8 mm Hg and 15.8  6.5 mm Hg, respectively
(P<.001). Similarly, their mean PVR decreased significantly
from a baseline of 3.6 1.9Woods units to 2.10 0.8Woods
units (P< .001). Their mean TPG also declined significantly
from a baseline of 12.6  5.3 mm Hg to 9.4  3.0 mm Hg;
P ¼ .001 (Table 2).Severe Pulmonary Hypertension
Severe PH (ie, medically unresponsive) was identified in
18 patients (mean PVR, 5.2  1.7 Woods units; mean TPG,
17.5  4.9 mm Hg). After LVAD support (mean duration,
170  111 days), all measurements of severe PH, including
PVR, TPG, SPAP, and DPAP, decreased significantly. Of
the 18 patients with severe PH, 4 required advanced medical
therapy (phosphodiesterase type 5 inhibitors) in addition to
LVAD support and standard vasodilatory therapy. We noted
no difference in the trend of change in pulmonary hemody-
namics compared with the remaining 32 patients with a BTT
without severe PH (Table 3, Figure 1).Effect on Mitral Regurgitation
Mitral regurgitation was graded as follows: 0 ¼ normal to
trace; 1 ¼ mild; 2 ¼ moderate; 3 ¼ moderately severe; and
4 ¼ severe mitral regurgitation. There was a significant re-
duction after LVAD placement in the severity of mitral regur-
gitation in patients with non-severe PH (baseline 1.96  1.3TABLE 2. Patient hemodynamics (n ¼ 50)
Mean ± SD Baseline Post-LVAD
Mean follow-up, d 0 135  60
SPAP, mm Hg* 55.2  13.4 35.9  10.8
DPAP, mm Hg* 27.3  6.8 15.8  6.5
Mean PAP, mm Hg* 36.7  8.8 22.5  7.5
Right atrial mean, mm Hg* 13.0  5.6 7.0  5.6
PCWP, mm Hg* 24.0  5.9 13.1  6.7
PVR, Woods units* 3.6  1.9 2.10  0.83
TPG, mm Hg* 12.6  5.3 9.43  3.0
CO, L/min* 3.9  1.3 4.8  1.3
CI* 2.0  0.5 2.4  0.5
SD, Standard deviation; LVAD, left ventricular assist device; SPAP, systolic pulmo-
nary artery pressure; DPAP, diastolic pulmonary artery pressure; PAP, pulmonary ar-
tery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular
resistance; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index.
*Statistically significant, P< .05.
The Journal of Thoracic and Cato 1.03 0.9, P¼ .003) and in patients with severe PH (base-
line 1.4 0.9 to 0.5 0.5, P¼ .01). In addition, none of the
patients in either group underwent a concomitant mitral valve
repair at the time of the LVAD implant.T
XPost-Left Ventricular Assist Device and Bridge-to-
Transplant Outcomes
In our population of 50 patients with a BTT, the survival
at 6 months by Kaplan–Meier analysis (alive or transplant
recipient) was 89.1%. The 6-month survival (alive or trans-
plant recipient) by Kaplan–Meier analysis in patients with
severe PH was 88.8% compared with 93.3% in patients
with non-severe PH (P ¼ not significant). There was an in-
creased incidence of right ventricular failure (9.3% [3/32] vs
0%, P ¼ .004) and neurologic events (15.6% [5/32] vs
5.6% [1/18] P¼ .03) in the patients without severe PH com-
pared with the patients with severe PH.
The overall mean time to transplant for all 50 patients was
259 180 days. The time to transplant in the group with se-
vere PH was 280  265 days, compared with 248  124
days in the group without severe PH (P ¼ not significant).
Of the 50 patients with a BTT, 32 (64%) have undergone
a transplant—11 (61%) of the 18 patients with severe PH
and 21 (65%) of the 32 patients without severe PH
(P ¼ not significant). The 1-month posttransplant hemody-
namic measurements of those 32 transplant recipients are
represented in Table 4.DISCUSSION
The discrepancy between the limited availability of donor
hearts and the ever-increasing number of patients with heart
failure has led to the increasing use of LVADs.2 The findings
from our current study extend our and others’ previous ob-
servations that continuous-flow devices, such as axial-flow
LVADs, allow favorable changes in the altered pulmonary
hemodynamics that are commonly seen in patients with
end-stage heart failure. Previous studies have shown a lesser
degree of left ventricular unloading with continuous-flowrdiovascular Surgery c Volume 140, Number 2 449
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FIGURE 1. Pulmonary hemodynamics in patients with a BTTwho are undergoing HeartMate II LVAD placement with (n¼ 18) and without (n¼ 32) severe
PH (n ¼ 18) at 2 different points: baseline (before LVAD placement) and after LVAD placement.
TABLE 4. Patient hemodynamics at 1 month posttransplant (n ¼ 32)
Mean follow-up, d 26.5  11.1
SPAP mm Hg 38.1  8.5
DPAP mm Hg 16.1  4.6
Mean PAP mm Hg 23.4  5.3
Right atrial mean mm Hg 8.5  3.9
PCWP mm Hg 13.8  4.9
PVR Woods Units 1.8  0.95
TPG mm Hg 9.8  4.4
CO L/min 5.4  1.5
CI (fick) 2.7  0.6
SPAP, Systolic pulmonary artery pressure;DPAP, diastolic pulmonary artery pressure;
PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR,
pulmonary vascular resistance; TPG, transpulmonary gradient; CO, cardiac output;
CI, cardiac index.
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X(vs pulsatile) devices but a similar degree of pressure unload-
ing under resting conditions.8-10 Other end points (eg,
exercise performance and cellular recovery) have also been
shown to be similar for the 2 types of devices.11,12 Thus,
partial unloading of the left ventricle may be sufficient to
favorably influence altered pulmonary hemodynamics in
patients with end-stage heart failure. Our observations
confirm that the HeartMate II LVAD can be used to reverse
medically unresponsive severe PH in patients with a BTT
and heart failure.
Several previous studies have identified multiple risk fac-
tors for adverse heart transplant survivals, including the need
for pretransplant mechanical circulatory support, PH, a prior
heart transplant, immunologic sensitization, and prolonged
donor ischemic times. Outcomes after mechanical circula-
tory support have vastly improved, and improved immuno-
modulatory regimens to treat the sensitized patient are now
available, yet PH remains a relative contraindication to
a heart transplant. Certainly, improved perioperative strate-450 The Journal of Thoracic and Cardiovascular Surggies (including the use of intravenous phosphodiesterase in-
hibitors, eg, milrinone and the use of inhaled pulmonary
vasodilators, eg, nitric oxide) have markedly decreased the
adverse impact of PH on outcomes posttransplant.13,14ery c August 2010
Placement of LVAD In BTT Heart Failure Patients with Severe PH
PH Responsive Persistence of Severe PH
Proceed with OHT
Add Oral Vasodilator 
Therapy e.g. Sildenafil
PH Responsive
Proceed with OHT
PH Non Responsive
Strategies include
Consider OHT with
Oversized donor
Shorter Ischemic time
Avoid high risk donor
Continued LVAD
Support
FIGURE 2. Algorithm at the University of Minnesota for the management
of patients with end-stage heart failure and severe PH who are undergoing
LVAD placement.
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XHowever, refractory or medically unresponsive PH is
definitely associated with a higher mortality rate after
a heart transplant and is therefore considered an absolute
contraindication to a heart transplant. More important,
some studies have identified even reversible PH as a risk
factor for a higher mortality rate posttransplant.15,16
Discrepancies in conclusions from various studies stem
from a lack of consensus on the definitions of PH and revers-
ibility, aswell as the various techniques used to predict revers-
ibility. The exact degree of PH that confers an unfavorable
prognosis is uncertain, but it remains a well-established risk
factor for both early and late mortality posttransplant.15,16
Even in the case of reversible PH, ongoing pharmacologic
interventions may be insufficient to maintain the degree of
PH within reasonable limits. Further, even patients with
reversible PH face the risk of a further increase in
pulmonary artery pressures after the dual insults of
cardiopulmonary bypass and blood product administration.
Given the adverse impact of even reversible PH on survival
posttransplant, more aggressive use of LVADs as a BTT
may be warranted even for patients with reversible PH.
Clearly, until now, the high morbidity and mortality rates
with the larger, limited-durability pulsatile devices have
limited the wider application of LVADs. But change is now
likely because of recently published data supporting the
improved functional status, the enhanced quality of life, and
the significantly reduced adverse complications experienced
with continuous-flow devices.17
As a result of this lack of definitive evidence (at least until
recently), concerns have lingered about the efficacy of
circulatory support (and its attendant effect on pulmonary
hemodynamics) provided by continuous-flow (vs pulsatile)
devices.18,19 Several series, using different types of
pulsatile devices, have documented their benefits in
patients with end-stage heart failure with PH. In one of thoseThe Journal of Thoracic and Caseries, Martin and colleagues20 described a patient in whom
a continuous-flow Jarvik 2000 (Jarvik Heart Inc, New York,
NY) was replaced with a HeartMate XVE because of inade-
quate pump flow. Concerns with continuous-flow devices
have stemmed from their mechanism of function, namely,
partial unloading (vs the more complete unloading provided
by pulsatile devices). However, it was recently shown that
patients with PH can be successfully bridged to a heart
transplant with continuous-flow devices, including the
MicroMed DeBakey (Micromed DeBakey, Houston, Tex)
and the INCOR LVAD (BerlinHeart AG, Berlin, Ger-
many).21-23 Etz and colleagues21 reported a significant
reduction in pulmonary artery pressures within 1 month after
LVAD implantation in most of their patients. However, the
ideal duration of LVAD support to optimize posttransplant
outcomes in patients with end-stage heart failure with severe
PH remains uncertain.
The majority of patients with mild-to moderate reversible
PH undergoing heart transplantation will demonstrate
significant and prompt reduction in pulmonary artery
pressures.24 However, there is a group of patients with
moderate-to-severe PH who may have persistent PH after
a successful heart transplant; posttransplant mortality is
noted to be higher in this subset of patients with PH.25 It
should be noted that in our study, posttransplant pulmonary
hemodynamics (including PVR, TPG, SPAP, and DPAP) in
the LVAD-supported patients undergoing a heart transplant
remained within normal limits even in the subgroup of
patients with severe PH.
Occasionally (as seen with 4 patients in our experience),
a patient with severe PH who is supported on an LVAD
may have persistently elevated pulmonary pressures refrac-
tory to LVAD support and will require additional pulmonary
vasodilator treatment. Such rare patients have no choice
other than to continue on LVAD support as destination
therapy, because their persistently elevated PVR makes
them ineligible for a heart transplant. These patients may
be removed from the transplant list, converting them to des-
tination therapy status. However, with time and additional
medical vasodilator therapy, most of these patients with
refractory PH will demonstrate some reduction in their pul-
monary artery pressures. Some patients with refractory PH
may be considered for a heart–lung transplant or heterotopic
transplant. Although both the latter 2 procedures are per-
formed rarely in the current era, the policy at the University
of Minnesota Medical Center is to strongly consider an over-
sized donor with a relatively shortened ischemic time for
orthotopic heart transplant for these patients as opposed to
a heart–lung or heterotopic transplant (Figure 2).
Study Limitations
This single-center study was limited by its relatively small
number of patients. In addition, there was no randomized
comparison group of patients treated with pulsatile devicesrdiovascular Surgery c Volume 140, Number 2 451
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Xto help us analyze the possible different impacts of the 2
types of devices on pulmonary hemodynamics. However,
all of our patients underwent LVAD placement over a rela-
tively short period of time, so their perioperative treatment
protocols were consistent.CONCLUSIONS
Continuous-flow LVAD support, when used as a BTT,
effectively improves pulmonary hemodynamics in patients
with end-stage heart failure. Adequate left ventricular decom-
pression achieved with continuous-flow LVAD support,
despite the partial LV unloading, can reverse significant PH
in patients with end-stage heart failure, making them eligible
for a heart transplant. Moreover, pulmonary hemodynamics
remain within normal limits in the posttransplant period,
even in patients with prior severe PH. This may have favor-
able implications for superior longer-term survival in these
transplant recipients because residual posttransplant PH has
been shown to be associated with decreased posttransplant
survival. Thus, the many advantages of the smaller,
continuous-flow LVADs (eg, improved durability and
reliability, and reduced incidence of adverse complications)
can be safely offered as a BTT to patients with heart failure
and PH.
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